BioSpace News Archive

CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody ® technology platform, today announced the planned retirement from CytomX of W. Michael Kavanaug

Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company (the “Company”) focused on commercializing novel products that address significant patient needs today reported financial results for its fiscal fourth quarter 2020, for the three month period ending June 30, 2020.

AmerisourceBergen Corporation (NYSE: ABC) today announced that it plans to release its results for the Fourth Quarter Fiscal 2020 on Thursday, November 5, 2020, prior to the opening of trading on the New York Stock Exchange

NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that it intends to offer and sell, subject to market and other conditions, $150.0 million of shares of its common stock in an underwritten public offering pursuant to NanoString’s shelf registration statement. In connection with this offering, NanoString expects to grant the underwriters

Medtronic plc announced that Omar Ishrak has decided not to stand for re-election at the Annual General Meeting in December and will retire as Executive Chairman and Chairman of its Board of Directors effective December 11, 2020.

Complete third quarter 2020 financial results will be announced on Tuesday, October 27, 2020 Preliminary third quarter 2020 product revenue ranging from $274 million to $278 million Full-year guidance for 2020 product revenue ranging from $1,124 million to $1,128 million

Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, announces the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976,

Paragon 28, Inc. is pleased to announce the appointment of Steve Deitsch to the position of Chief Financial Officer.

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a rolling submission to the European Medicines Agency (EMA) for BNT162b2, the lead candidate from the companies’ vaccine development program against COVID-19.

Eisai Co., Ltd. announced today that it has entered into a joint research agreement with four research organizations (KAN Research Institute, National Center for Global Health and Medicine, Nagasaki University, and Yokohama City University) in Japan concerning the “Development of Therapeutics to Prevent the Aggravation of the Novel Coronavirus Infectious Disease (COVID-19)”